Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 46Other solid neoplasm 46Lymphoid 1Genitourinary 1Breast 1

Conditions

Lymphoma 6Lymphoma, Non-Hodgkin 4Sezary Syndrome 3Neoplasm Metastasis 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Follicular 3Central Nervous System Neoplasms 3Waldenstrom Macroglobulinemia 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mesothelioma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Burkitt Lymphoma 2Brain Neoplasms 2Uveal Melanoma 1Thrombocythemia, Essential 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Oligodendroglioma 1

Interventions

enzalutamide 1entinostat 1abemaciclib 1Polymerase Chain Reaction 1Pemetrexed 1Paclitaxel 1Midazolam 1Microarray Analysis 1Letrozole 1LY3023414 1In Situ Hybridization, Fluorescence 1Immunoenzyme Techniques 1Gene Expression Profiling 1Fulvestrant 1Flow Cytometry 1Fentanyl 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Pemetrexed × Lymphoid × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡